KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC 50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity In Vitro KIF18A-IN-6 (Compound 134; 7 days) inhibits JIMT-1, HCC-15 and NIH-OVCAR3 cells viability with IC 50 s of 0.0040, 0.0051 and 0.0051 μM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HCC-15, JIMT-1 and NIH-OVCAR3 Concentration: Incubation Time: 7 days Result: Inhibited cell viability with IC 50 s of 0.0040, 0.0051 and 0.0051 μM against JIMT-1, HCC-15 and NIH-OVCAR3 cells, respectively. In Vivo KIF18A-IN-6 (Compound 134; 10-60 mg/kg; p.o.; twice or once a day for 1 month) inhibits HCC15 and OVCAR3 tumor growth in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SCID Beige mice, HCC15 tumor model Dosage: 10, 30 and 60 mg/kg Administration: PO, twice a day for 1 month Result: Inhibited tumor growth by 61±10%, 89±7% and 94±5% at 10, 30 and 60 mg/kg, respectively. Animal Model: Balb/C nude mice, OVCAR3 tumor model Dosage: 10, 30 and 60 mg/kg Administration: PO, twice or once a day for 1 month Result: Completely inhibited tumor growth (over 100%) over 30 mg/kg. Form:Solid IC50& Target:IC50: 0.016 μM (KIF18A microtubule-dependent ATPase activity)